Clinical trials: Frontotemporal Degeneration (FTD)
Frontotemporal Dementia, Caregiver Burden
STELLA-FTD: Examination of a Behavior Change Intervention for FTD Family Care Partners
The purpose of this nationwide study is to test STELLA-FTD (Support via Telehealth: Living and Learning with Advancing Alzheimer's Disease)-FTD, an intervention to specifically address the needs of family Care Partners of persons…
- Conditions
- Frontotemporal Dementia, Caregiver Burden, Primary Progressive Aphasia (PPA), Corticobasal Syndrome
- Trial name
- STELLA-FTD (NCT06613204)
- Testing
- STELLA-FTD Control, STELLA-FTD Test
- Where
- United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Alzheimer's Tau Platform: Regimen A - AADvac1
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Trial name
- ATP (NCT07167966)
- Testing
- AADvac1, Donanemab
- Where
- 7 sites in United States
- Volunteers
- 450 people
- Sponsor
- Paul S. Aisen
Corticobasal Syndrome, Progressive Supranuclear Palsy
Diagnosing Frontotemporal Lobar Degeneration
To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes
- Conditions
- Corticobasal Syndrome, Progressive Supranuclear Palsy, Behavioral Variant Frontotemporal Dementia, Semantic Dementia
- Trial name
- NCT02964637
- Testing
- Observational Study
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Time of Death
Estimate of the TSD Based on the Quantification of the Tau Protein in CSF
Background: The accurate estimation of the time of death is a challenge in forensic medicine, as the methods routinely used to assess the post-mortem interval (PMI) are far from being precise.
- Trial name
- NCT03845439
- Testing
- Lumbar puncture
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Montpellier
Frontotemporal Dementia
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
This study will evaluate the effects on emotions and neural activity of a one time dose of intranasal oxytocin vs. placebo in patients with FTD and healthy controls.
- Trial name
- IEMO (NCT01937013)
- Testing
- Intranasal oxytocin, Saline Nasal Mist
- Where
- Canada
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit
Alzheimer Disease
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.
- Trial name
- MKADAD (NCT04104659)
- Testing
- MK 6240
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Alzheimer's Disease, Mild Cognitive Impairment
A Composite MR Neuroimaging Marker for Alzheimer's Disease
The purpose of this study is to use a functional MRI (fMRI) index to compare the brain activity of healthy volunteers to that of people with mild cognitive impairment (MCI) and Alzheimer's disease.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Frontotemporal Dementia
- Trial name
- NCT01615666
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Genetic Study of Familial and Sporadic ALS/Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders
The investigators laboratory has been studying families with a history of ALS for more than 30 years and is continuing to use new ways to understand how genes may play a role in ALS, motor neuron disease and other neuromuscular…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, PLS, Motor Neuron Disease
- Trial name
- NCT01459302
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
The goals of this study are: (1) to better understand the relationship between the phenotype and genotype of amyotrophic lateral sclerosis (ALS) and related diseases, including primary lateral sclerosis (PLS), hereditary spastic…
- Conditions
- Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia
- Trial name
- NCT02327845
- Where
- 15 sites in United States, Germany and 1 more
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- University of Miami
Alzheimer Disease, Semantic Dementia
Memory and Social Interactions
Memory and social interaction are intimately linked. On the one hand, social interaction is a privileged context for learning, and on the other hand, appropriate social interactions involve remembering the partners encountered…
- Trial name
- MEM&SO (NCT05800028)
- Testing
- Learning new information
- Where
- France
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Frontotemporal Dementia
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
This is an open-label, single subject, expanded access protocol (EAP) of the LAM-002A investigational product administered orally at 125 mg BID for 52 weeks.
- Trial name
- NCT05483322
- Testing
- LAM-002A
- Sponsor
- IRulya Therapeutics Inc.
Neurodegenerative Diseases
Continuation Study for Latozinemab
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
- Trial name
- NCT06111014
- Testing
- Latozinemab
- Where
- 18 sites in United States, Belgium and 8 more
- Volunteers
- 17 people
- Sponsor
- Alector Inc.
Alzheimer Disease (AD)
Daridorexant for Alzheimer Disease Prevention
This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease.
- Trial name
- PAD-DORA (NCT07213349)
- Testing
- Daridorexant 50 mg
- Where
- Canada
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Postoperative Delirium
Association of Plasma Biomarkers for Neurological Injury and Postoperative Delirium After Cardiac Surgery
Delirium is one of the most common complications after cardiac surgeries, incidence of which is 20~70%. Causes and pathophysiology of delirium has not been elucidated yet, however, inflammatory response of the nervous system…
- Trial name
- NCT04194411
- Where
- South Korea
- Volunteers
- 152 people
- Sponsor
- Yonsei University
Dementia, Alzheimer Disease
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
To develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including Mild Cognitive Impairment (MCI) and dementia due to any neurodegenerative disease…
- Conditions
- Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- CRND TorCA (NCT06529744)
- Where
- 4 sites in Canada
- Volunteers
- 500 people
- Sponsor
- University Health Network, Toronto
Dementia, Mild Cognitive Impairment
SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia
Assistive Technologies (ATs) can help people living with dementia (PwD) maintain their everyday activity. Still, there is a gap between potential and supply. Involving future users can close the gap.
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease, Dementia With Lewy Bodies
- Trial name
- SAIN_UMR (NCT05885620)
- Testing
- drinking reminder and cognitive task (smartwatch-based application)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Rostock
Semantic Dementia
Evaluation of a Transcranial Stimulation With Direct Current on Language Disorders in Semantic Dementia
Within the spectrum of fronto-temporal lobar degeneration (FTLD) semantic dementia (SD) causes profound language dysfunction. SD damages semantic processing typically in the temporal poles (anterior temporal lobes, ATL).
- Trial name
- STIM-SD (NCT03481933)
- Testing
- Transcranial stimulation
- Where
- 2 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease
Learning Amyloid and Tau Results
This is a prospective, single-cohort, single-center, observational study to assess if learning one's Alzheimer's disease biomarker test result impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and to…
- Trial name
- NCT07222930
- Testing
- Disclose amyloid, tau results, Follow-up Assessments
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Primary Progressive Aphasia(PPA)
Long Term Effect of Brain Stimulation in PPA
The goal of this clinical trial is to investigate the effect of non-invasive brain stimulation techniques in the progression of primary progressive aphasia for 6 months.
- Trial name
- RECONNECT-PLUS (NCT07158216)
- Testing
- TMS, tDCS
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Hospital San Carlos, Madrid